Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today: Gyre Therapeutics, Inc. GYRE is a biotechnology company which is focused on organ fibrosis and inflammatory diseases. The ...

Full year 2026 revenue guidance of $100.5 to $111.0 million affirmed. NDA for F351 (hydronidone) for CHB-associated liver ...

SAN DIEGO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across ...

Gyre Therapeutics, Inc. (“Gyre”, “Gyre Therapeutics” or the “Company”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company with operations in the United States and China, today ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

The first tropical storm of 2025 could spin up before the official start of the Atlantic hurricane season, kicking off what is predicted to be a dynamic year for hurricanes. Around the middle of May, ...

SAN DIEGO, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a ...